Expression and Clinico pathological correlation of Rab 25 Protein in Human Ovarian cancers.
Biomarkers have contributed to the management of ovarian cancers by monitoring response to treatment, recurrence distinguishing benign and malignant pelvic masses as well as attempting to detect disease at an earlier stage. In line with this perspective Rab25 protein is incorporates also as the biomarker of early detection of ovarian cancer however details reports are lacking in the pattern of its distribution in different subtypes of ovarian cancers. This was a retrospective study, of a raw data from Biomax .US with Identification Number: OV2085: including Ovary cancer survey tissue array (1 of 5), including TNM, clinical stage and pathology grade, 104 cases; cores. Where a total of 94 patients suffering from ovarian cancers were enrolled and we carry immunohistochemistry quantification for assessing the expression and distribution of Rab25 protein and clinicopathological parameters. Of note, 10 cases of normal ovarian tissues were used as control from healthy subject. Our results show that Rab25 is highly expressed in all type of ovarian cancer; we also conducted the assessment of the association of Rab25 protein with clinicopathological factors including age, staging, grading, and metastasis, which were analyzed using the Pearson’s χ2 test. The results indicated that Rab25 protein expression was significantly associated with age, stage grading, and metastasis. Our reports showed that Rab25 protein expression and the prevalence of the ovarian cancers were cell type-and age-dependent. Rab 25 protein is abundantly expressed in the germ cell tumor, sex cord stroma, then less in the epithelial cells’ tumor. Suggesting that Rab25 protein could be a novel diagnostic biomarker for the germ cells ovarian tumor.
Keywords: Ovarian cancer, Rab25, prevalence of ovarian cancer clinicopathologic parameters
